Trials / Recruiting
RecruitingNCT06891560
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enfortumab Vedotin | intravenously on Days 1, 8 and 15 of a 28-day cycle-dose can be done up to +/-3 days after the scheduled day of administration |
Timeline
- Start date
- 2025-03-31
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2025-03-24
- Last updated
- 2026-03-20
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06891560. Inclusion in this directory is not an endorsement.